Mitochondrial cleanup in Parkinson’s is more complex than assumed
In Parkinson’s disease, specific brain cells die preferentially. Researchers long believed a well-known mitochondrial quality control system held the key. But simply switching that system on turns out not to be enough.
Mitochondria are the energy-generating organelles of cells. When they become damaged, they are normally removed through a process called mitophagy: damaged mitochondria are recognized and broken down. The PINK1/Parkin pathway is the best-characterized mechanism for this, and it demonstrably functions worse in Parkinson’s patients.
Yet therapies that attempt to stimulate this pathway have so far yielded little success. The researchers argue this is because the pathway has been treated like a simple switch. Mitophagy is instead a chain of sequential steps, from damage recognition through protein labeling to lysosomal degradation. If any step in that chain stalls, accelerating only the first step does not help.
A self-reinforcing network of damage
In Parkinson’s, the accumulation of misfolded alpha-synuclein protein interferes with the normal course of mitophagy. Lysosomes, the cell’s degradation factories, are also impaired. And neuroinflammation (chronic inflammation within the nervous system) compounds the problem. The result is a self-sustaining network of damage in which upstream activation of PINK1/Parkin does not translate into actual mitochondrial clearance.
The authors therefore call for a different readout in research: not whether the pathway is active, but whether mitophagy is actually completed. That distinction has direct consequences for how clinical studies are designed and how patients are selected. Early intervention, before multiple steps in the chain are already disrupted, appears more promising under this framework. This is a review article, not an original clinical experiment.
What this means for treatment
There is no immediate clinical application. But understanding why earlier PINK1-targeted therapies disappointed has improved. That makes this review relevant for anyone following the state of Parkinson’s research and mitochondrial aging. The piece was published via Fight Aging.
Want to research this yourself? Search for: PINK1 Parkin mitophagy Parkinson’s, mitochondrial quality control neurodegeneration, alpha-synuclein lysosomal dysfunction